Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF

Alice M Jackson,Pooja Dewan,Inder S. Anand,Jan Belohlavek,Olof Bengtsson,Rudolf A. de Boer,Michael Böhm,David W. Boulton,Vijay K. Chopra,David L. DeMets,Kieran F. Docherty,Andrej Dukát,Peter J. Greasley,Jonathan G. Howlett,Silvio E. Inzucchi,Tzvetana Katova,Lars Køber,Mikhail Kosiborod,Anna Maria Langkilde,Daniel Lindholm,C Ljungman,Felipe Martinez,Eileen OMeara,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Sergey Tereshchenko,Subodh Verma,Pardeep S. Jhund,John J.V. McMurray

Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF

2020

Background: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death in patients with heart failure and reduced ejection fraction. We examined e...

Keywords:

Internal medicine
in patient
Heart failure
Medicine
SGLT2 Inhibitor
Dapagliflozin
Diuretic
Cardiology
Ejection fraction
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations